Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing drug candidates for unmet medical need. The company's product candidate consists of AT-001, for the treatment of Diabetic Cardiomyopathy; AT-007, for the treatment of Galactosemia and AT-003, for the treatment of diabetic retinopathy which are in clinical stage. Applied Therapeutics Inc. is based in New York, United States.
| Revenue (Most Recent Fiscal Year) | $0.46M |
| Net Income (Most Recent Fiscal Year) | $-105.62M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.44 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -16357.52% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -184.67% |
| Return on Assets (Trailing 12 Months) | -84.02% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.00 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.00 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.49 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.15 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.73 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.43 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 141.58M |
| Free Float | 139.31M |
| Market Capitalization | $52.95M |
| Average Volume (Last 20 Days) | 1.45M |
| Beta (Past 60 Months) | 1.86 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.31% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |